Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment

Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment

Targeting the immune checkpoint receptors cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed cell death 1 ligand 1 (PD-L1) represents a very attractive treatment modality for tumor patients. The administration of antibodies against these receptors can pr...

Full description

Bibliographic Details
Main Authors: Antje Tunger, Maximilian Kießler, Rebekka Wehner, Achim Temme, Friedegund Meier, Michael Bachmann, Marc Schmitz
Format: Article
Language:English
Published: MDPI AG 2018-03-01
Series:Biomedicines
Subjects:
cancer immunotherapy
immune monitoring
immune checkpoints
cytotoxic T lymphocyte antigen 4
programmed cell death protein 1
programmed cell death 1 ligand 1
Online Access:http://www.mdpi.com/2227-9059/6/1/26

Internet

http://www.mdpi.com/2227-9059/6/1/26

Similar Items